



## 저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

공학석사학위논문

**Water Soluble Polymerized Metabolic  
Precursors Based on  
PEG-PAMAM-Ac<sub>3</sub>ManNAz System  
for Epigenetic Targeting**

수용성 고분자화 대사 전구체를 이용한  
후성 표적화 전략

2017 년 8 월

서울대학교 공과대학원  
재료공학부

고 은 호

# **ABSTRACT**

## **Water Soluble Polymerized Metabolic Precursors Based on PEG-PAMAM-Ac<sub>3</sub>ManNAz System for Epigenetic Targeting**

Eun Ho Kho

Department of Materials Science and Engineering

College of Engineering

Seoul National University

Over the past several decades, various drug delivery systems have been studied to minimize the side effects of anticancer agents and to increase delivery efficiency to cancer. Despite the development of numerous targeting moieties, several obstacles remain. Tumor heterogeneity and quantitative limitation of targeted biomolecules are reasons why chemotherapy failed to suppress cancers completely.

In this study, we developed hydrolysable polymerized metabolic precursors (pMPs) by conjugating PEG-PAMAM linear dendritic block copolymers (LDBC) and triacetylated N-azidoacetyl-mannosamine

(Ac<sub>3</sub>ManNAz) via *Steglich* esterification. As the carboxylic acids of the dendron disappear, pMPs became amphiphilic block copolymers and formed self assembly of 150 nm in aqueous condition. Regardless of genetic phenotypes of tumor cells, pMPs can generate ‘receptor-like’ azide groups on the cancer cell surface. Furthermore, the azide groups were visualized by ADIBO-Cy5.5 via copper-free click chemistry *in vitro* condition. It is expected that pMPs have synergy with the enhanced permeability and retention (EPR) effect and hypersialylation of tumor cells to enable tumor cell specific glycan labeling *in vivo* condition.

**Keywords:** Tumor Heterogeneity, Metabolic Glycoengineering, Epigenetic Targeting, Copper-Free Click Chemistry, Linear-Dendritic Block Copolymer, Self-Assembly

**Student number:** 2015-20797

# CONTENTS

<b>Abstract .....</b>	<b>i</b>
<b>Contents .....</b>	<b>iii</b>
<b>List of figures and tables .....</b>	<b>v</b>
<b>1. Introduction .....</b>	<b>1</b>
<b>2. Experiments .....</b>	<b>5</b>
<b>2.1. Materials .....</b>	<b>5</b>
<b>2.2. Instruments.....</b>	<b>5</b>
<b>2.3. Synthetic procedure for PEG-PAMAM linear dendritic block     copolymers.....</b>	<b>6</b>
2.3.1. Michael addition of amines .....	6
2.3.2 Exhaustive amidation of methyl esters .....	7
2.3.3. Synthesis of PEG-PAMAM [G0.5] Dendron .....	7
2.3.4. Synthesis of PEG-PAMAM [G1.0] Dendron .....	8
2.3.5. Synthesis of PEG-PAMAM [G1.5] Dendron .....	8
2.3.6. Synthesis of PEG-PAMAM [G2.0] Dendron .....	9
2.3.7. Synthesis of PEG-PAMAM [G2.5] Dendron .....	9
2.3.8. Synthesis of PEG-PAMAM [G3.0] Dendron .....	10

2.3.9. Synthesis of Succinamic acid terminated PEG-PAMAM [G3.0] .....	10
2.4. Conjugation of Ac <sub>3</sub> ManNAz to PEG-PAMAM [G3.0] .....	11
2.5. Preparation of self assembly .....	12
2.6. <i>In vitro</i> release of Ac <sub>3</sub> ManNAz .....	12
2.7. Cell culture .....	12
2.8. Cell viability assay .....	13
2.9. Cellular imaging to determine the generated azide groups .....	13
2.10. Western blot analysis of cells.....	14
 <b>Results and Discussion .....</b>	<b>16</b>
3.1. Synthesis and characterization of succinamic acid terminated PEG-PAMAM [G3.0].....	16
3.2. Synthesis and characterization of pMPs .....	22
3.3. Formation of self assembly .....	26
3.4. <i>In vitro</i> release of Ac <sub>3</sub> ManNAz .....	28
3.5. <i>In vitro</i> studies of pMPs .....	30
 <b>4. Conclusions .....</b>	<b>34</b>
 <b>5. References .....</b>	<b>35</b>

## List of Figures and Tables

**Figure 1.** (a) Schematic illustration of the targeting strategy to overcome tumor heterogeneity using metabolic glycoengineering and copper-free click chemistry. (b) Chemical structure of pMPs and its self-assembly formation

**Figure 2.**  $^1\text{H}$  NMR spectra of (a) mPEG-G0.5, (b) mPEG-G1.0, (c) mPEG-G1.5, (d) mPEG-G2.0, (e) mPEG-G2.5 in  $\text{CDCl}_3$  and (f) mPEG-G3.0, (g) mPEG-G3.0-COOH in  $\text{D}_2\text{O}$

**Figure 3.**  $^1\text{H}$  NMR spectra of (a)  $\text{Ac}_3\text{ManNAz}$  and (b) pMPs in  $\text{D}_2\text{O}$

**Figure 4.** GPC spectra of pMPs and mPEG-G3.0

**Figure 5.** Size distribution of self-aggregates

**Figure 6.** GPC spectra of pMPs on time-dependent hydrolysis

**Figure 7.** Viability of HT-29 cells treated with pMPs for 48 hours

**Figure 8.** Azide group generation on cell surface in various concentration of pMPs (a) Visualization of azide groups on the surface of HT-29 tumor cells  
(b) Coomassie staining and western blot analysis of HT-29 tumor cells

**Figure 9.** Time dependent azide group generation on cell surface after pMPs treatment (a) Visualization of azide groups on the HT-29 tumor cell surface  
(b) Coomassie staining and western blot analysis of HT-29 tumor cells



# 1. INTRODUCTION

Metabolic oligosaccharide engineering was pioneered by Reutter and co-workers to modify the acyl side chains on cell surface sialic acids in living cells using unnatural sugars as the metabolic precursors<sup>1-2</sup>. After that Carolyn Bertozzi's group reported bioorthogonal functional groups could be incorporated into cell membrane sialic acid treating with N-acetylmannosamine derivatives<sup>3-4</sup>. Once the unnatural functional group is integrated into sialic acid, it is treated with a probe molecule bearing complementary bioorthogonal functionality for precise glycan imaging<sup>5</sup>. As of now, many groups employed this technique for studying various purposes like glycoproteomics, embryogenesis<sup>6-7</sup>.


As research on drug delivery systems continues, lots of targeting moieties have been developed that can target only tumors<sup>8-10</sup>. Despite the numerous targeting moieties developed, tumor heterogeneity is one of the reasons why chemotherapy failed to completely suppress cancer<sup>11</sup>. Recent studies reported extensive diversity of genetic phenotype both between and within tumors<sup>12-13</sup>. For this reason, conventional active targeting method using specific biomolecule could not deliver therapeutic agent to the entire cancer. In addition, the limited number of biological receptors on tumor cells is an obstacle to increasing delivery efficiency<sup>14</sup>.

To overcome these limitations, we employed a strategy to artificially introduce target receptors into tumor cells. When cancer cells ingest azido sugar as a metabolite, the azide group is expressed on the cell surface regardless of the genetic phenotype of the cells (Figure 1a). Furthermore tumor cells showed increased expression of sialic acid sugars on the surface. Owing to their high expression of sialic acids, this approach could improve efficacy<sup>15</sup>. In order to selectively express azide groups in cancer cells, it is important to transport metabolites intensively to cancer tissues.

In our previous study, we developed polymerized metabolic precursors (pMPs) by conjugating triacetylated N-azidoacetyl-mannosamine (Ac<sub>3</sub>ManNAz) and generation 4 poly(amido- amine) (PAMAM [G4.0]). However, these materials have some drawbacks about water solubility and targeting ability. Herein, we chose PEG-PAMAM linear dendritic block copolymer(LDBC) to overcome the defects. We easily synthesized PEG-PAMAM LDBC using mPEG-NH<sub>2</sub> as a core initiator. Since the properties of mPEG-PAMAM are mainly determined by PEG, the purification required for the synthesis of PEG-PAMAM was carried out by simple precipitation method. Polymerized metabolic precursor(pMPs) were synthesized by conjugating PEG-PAMAM and triacetylated N-azidoacetyl-mannosamine(Ac<sub>3</sub>ManNAz) via Steglich esterification reaction. Since the solubility of the dendritic block is determined by its terminal surface, it becomes hydrophobic after the coupling with Ac<sub>3</sub>ManNAz<sup>16</sup>. As a result,

amphiphilic nature of pMPs led to form self-assembly in aqueous condition. The size of self-assembly on the aqueous condition was characterized to be about 150 nm, which is a suitable size to exhibit the EPR effect (Figure 1b).

The human colon adenocarcinoma cells (HT-29) were treated with pMPs. Ester bonds of pMPs were hydrolyzed and release free form  $\text{Ac}_3\text{ManNAz}$ . Our method generates azide groups on the tumor cell surface and these cells including subpopulation of tumor cells. Azide groups on the cell membrane is visualized by copper free click reaction with ADIBO-Cy5.5.



**Figure 1.** (a) Schematic illustration of the targeting strategy to overcome tumor heterogeneity using metabolic glycoengineering and copper-free click chemistry. (b) Chemical structure of pMPs and its self-assembly formation

## 2. EXPERIMENTS

### 2.1 Materials

Methoxy PEG amine (MW : 2K) (mPEG-NH<sub>2</sub>) was obtained from Sunbio (Gunpo, Korea). Anhydrous methanol, Methyl acrylate, Ethylenediamine (EDA), Succinic anhydride, N,N'-Dicyclohexylcarbodiimide (DCC), 4-(Dimethylamino) pyridine (DMAP) were purchased from Sigma-Aldrich (St. Louis, MO, USA). EDA was distilled with calcium hydride before use in the experiments. Dichloromethane (MC) was obtained from Daejung Chemicals and Metals Co. (Goryeong, Korea). MC was dried over calcium hydride. Triacetylated *N*-azidoacetyl-*D*-mannosamine (Ac<sub>3</sub>ManNAz), azadibenzocyclooctyne-Cy5.5 (ADIBO-Cy5.5) were achieved from FutureChem (Seoul, Korea).

### 2.2 Instruments

<sup>1</sup>H NMR analysis was performed by Bruker Advance 300 MHz spectrometer using CDCl<sub>3</sub>-*d*<sub>6</sub> or D<sub>2</sub>O as a solvent at room temperature. Molecular weight change due to hydrolysis was measured by gel permeation chromatography (GPC) with Shimadzu RID-10A refractometer equipped with Styragel HR 3, HR 4, HR 4E columns in series. THF was used as an eluent with the flow rate of 1.0 mL/min and PEG standards were used for

calibration. Measurement of size was performed by Otsuka ELS-Z (Taipei, Taiwan). All cellular images were obtained by a confocal laser microscope (Leica TCS SP8) (Wetzlar, Germany) with 405 diode (405 nm) and He-Ne (633 nm) lasers.

## **2.3 Synthetic Procedure for PEG-PAMAM Linear Dendritic Block Copolymers**

Synthesis of the PEG-PAMAM linear dendritic block copolymers is a two step process (1) Michael addition of amine groups and (2) exhaustive amidation of the resulting methyl esters with large excess of ethylenediamine.

### **2.3.1 Michael addition of amines**

First, 2-neck round bottom flask was charged with methyl acrylate (100.0 equiv of amine). Amine terminated compounds/methanol solution was added at room temperature under nitrogen atmosphere. This reaction was carried out at 40 °C. Whether the reaction is complete was confirmed by using nihydriin test and chloranil test. After the Michael addition reaction was finished, the solvent and excess methyl acrylate was evaporated with a rotary evaporator. The white sticky residue was precipitated in cold diethyl

ether to remove residual impurities and filtered off to give the product, a white solid. The solid product was dried under vacuum.

### 2.3.2 Exhaustive amidation of methyl esters

Ester terminated compound was dissolved in anhydrous methanol and added to ethylenediamine (200.0 equiv of ester) slowly at room temperature under nitrogen atmosphere. The reaction is carried out at 45 °C. After 4 days, methanol and ethylenediamine were removed under vacuum. The crude product was precipitated in cold diethyl ether and filtered off to give a product. The product was a white solid and was dried over vacuum.

### 2.3.3 Synthesis of PEG-PAMAM [G0.5] Dendron

mPEG-PAMAM [G0.5] was synthesized using the procedure described in section 2.3.1., starting from mPEG-amine (1.00 g, 0.5 mmol) and methyl acrylate (8.61 g, 100.00 mmol) in 5.0 mL anhydrous methanol. The mixture was purified by precipitation in cold ether to give white solid (1.02 g, 93.9 %).

$^1\text{H}$  NMR in  $\text{CDCl}_3-d_6$ :  $\delta_{\text{PEG}}(\text{CH}_3\text{O}) = 3.3684$  (s) ;  $\delta_{\text{PEG}}(\text{CH}_2\text{CH}_2\text{O}) = 3.6327$  (m) ;  $\delta_{\text{PAMAM}}(-\text{COOCH}_3) = 3.6552$  (s)  $\delta_{\text{PAMAM}}(-\text{CH}_2\text{COOCH}_3) = 2.4396$  (t) ;  $\delta_{\text{PAMAM}}$  (protons next to tertiary amines) = 2.6 - 2.8 (m)

### 2.3.4 Synthesis of PEG-PAMAM [G1.0] Dendron

mPEG-PAMAM [1.0] was synthesized using the procedure described in section 2.3.2., starting from mPEG-G0.5 (0.92 g, 0.42 mmol) and ethylenediamine (10.18 g, 169.41 mmol) in 5.0 mL anhydrous methanol. The mixture was purified by precipitation in cold ether to give white solid (0.85 g, 88.0 %).

$^1\text{H}$  NMR in  $\text{CDCl}_3-d_6$ :  $\delta_{\text{PEG}}(\text{CH}_3\text{O}) = 3.3766$  (m) ;  $\delta_{\text{PEG}}(\text{CH}_2\text{CH}_2\text{O}) = 3.6403$  (m) ;  $\delta_{\text{PAMAM}}(-\text{CH}_2\text{CONH}) = 2.3824$  (t) ;  $\delta_{\text{PAMAM}}(-\text{CONHCH}_2) = 3.3042$  (q) ;  $\delta_{\text{PAMAM}}$  (protons next to primary and tertiary amines) = 2.64 - 2.84 (m)

### 2.3.5 Synthesis of PEG-PAMAM [G1.5] Dendron

mPEG-PAMAM [G1.5] was synthesized using the procedure described in section 2.3.1., starting from mPEG-G1.0 (0.81 g, 0.36 mmol) and methyl acrylate (12.52 g, 145.40 mmol) in 4.0 mL anhydrous methanol. The concentrate was purified by precipitation in cold ether to give white solid (0.86 g, 91.8 %).

$^1\text{H}$  NMR in  $\text{CDCl}_3-d_6$ :  $\delta_{\text{PEG}}(\text{CH}_3\text{O}) = 3.3700$  (s) ;  $\delta_{\text{PEG}}(\text{CH}_2\text{CH}_2\text{O}) = 3.6340$  (m) ;  $\delta_{\text{PAMAM}}(-\text{COOCH}_3) = 3.679$  (s) ;  $\delta_{\text{PAMAM}}(-\text{CH}_2\text{CONH}) = 2.3593$  (t) ;  $\delta_{\text{PAMAM}}(-\text{CONHCH}_2) = 3.2616$  (q) ;  $\delta_{\text{PAMAM}}(-\text{CH}_2\text{COOCH}_3) = 2.4227$  (t) ;  $\delta_{\text{PAMAM}}$  (protons next to tertiary amines) = 2.50 – 2.83 (m)



### 2.3.6 Synthesis of PEG-PAMAM [G2.0] Dendron

mPEG-PAMAM [2.0] was synthesized using the procedure described in section 2.3.2., starting from mPEG-G1.5 (0.78 g, 0.30 mmol) and ethylenediamine (14.58 g, 242.55 mmol) in 4.5 mL anhydrous methanol. The mixture was purified by precipitation in cold ether to give white solid (0.68 g, 84.0 %).

$^1\text{H}$  NMR in  $\text{CDCl}_3-d_6$ :  $\delta_{\text{PEG}}(\text{CH}_3\text{O}) = 3.3809$  (s) ;  $\delta_{\text{PEG}}(\text{CH}_2\text{CH}_2\text{O}) = 3.6444$  (m) ;  $\delta_{\text{PAMAM}}(-\text{CH}_2\text{CONH}) = 2.3689$  (m) ;  $\delta_{\text{PAMAM}}(-\text{CONHCH}_2) = 3.2677$  (m) ;  $\delta_{\text{PAMAM}}$  (protons next to tertiary and primary amines) = 2.52 - 3.00 (m)

### 2.3.7 Synthesis of PEG-PAMAM [G2.5] Dendron

mPEG-PAMAM [G2.5] was synthesized using the procedure described in section 2.3.1., starting from mPEG-G2.0 (0.69 g, 0.26 mmol) and methyl acrylate (17.69 g, 205.60 mmol) in 8.0 mL anhydrous methanol. The concentrate was purified by precipitation in cold ether to give white solid (0.75 g, 87.0 %).

$^1\text{H}$  NMR in  $\text{CDCl}_3-d_6$ :  $\delta_{\text{PEG}}(\text{CH}_3\text{O}) = 3.3744$  (s) ;  $\delta_{\text{PEG}}(\text{CH}_2\text{CH}_2\text{O}) = 3.643$  (m) ;  $\delta_{\text{PAMAM}}(-\text{COOCH}_3) = 3.672$  (m) ;  $\delta_{\text{PAMAM}}(-\text{CH}_2\text{CONH}) =$

2.375 (t) ;  $\delta_{\text{PAMAM}} (-\text{CONHCH}_2) = 3.273$  (q) ;  $\delta_{\text{PAMAM}} (-\text{CH}_2\text{COOCH}_3) = 2.435$  (t) ;  $\delta_{\text{PAMAM}}$  (protons next to tertiary amines) = 2.51 – 2.81 (m)

### 2.3.8 Synthesis of PEG-PAMAM [G3.0] Dendron

mPEG-PAMAM [3.0] was synthesized using the procedure described in section 2.3.2., starting from mPEG-G2.5 (0.70 g, 0.21 mmol) and ethylenediamine (19.95 g, 331.99 mmol) in 5.0 mL anhydrous methanol. The mixture was purified by precipitation in cold ether to give white solid (0.47 g, 63.0 %).

$^1\text{H}$  NMR in  $\text{D}_2\text{O}$  :  $\delta_{\text{PEG}}(\text{CH}_3\text{O}) = 3.298$  (s) ;  $\delta_{\text{PEG}}(\text{CH}_2\text{CH}_2\text{O}) = 3.620$  (m) ;  $\delta_{\text{PAMAM}} (-\text{CH}_2\text{CONH}) = 2.364$  (q)  $\delta_{\text{PAMAM}} (-\text{CONHCH}_2) = 3.216$  (m)  $\delta_{\text{PAMAM}}$  (protons next to tertiary and primary amines) = 2.54 – 2.87 (m)

### 2.3.9 Synthesis of Succinamic Acid Terminated PEG-PAMAM [G3.0]

25 mL round bottom flask was charged with mPEG-G3.0 (0.5 g, 0.14 mmol) and succinic anhydride (0.13 g, 1.25 mmol) and dissolved in anhydrous MC (8.00 ml). The solvent was evaporated by rotary evaporator and the concentrate was dissolved in  $\text{H}_2\text{O}$  to degrade succinic anhydride.  $\text{H}_2\text{O}$  is removed under vacuum and precipitated in diethyl ether 3 times to remove succinic acid.

$^1\text{H}$  NMR in  $\text{D}_2\text{O}$  :  $\delta_{\text{PEG}}(\text{CH}_3\text{O}) = 3.310$  (s) ;  $\delta_{\text{PEG}}(\text{CH}_2\text{CH}_2\text{O}) = 3.618$  (m) ;  $\delta_{\text{PAMAM}}(-\text{CH}_2\text{CONH}) = 2.404$  (m) ;  $\delta_{\text{PAMAM}}(-\text{CONHCH}_2) = 3.296$  (m)  $\delta_{\text{PAMAM}}(-\text{CONHCH}_2\text{CH}_2\text{NHCO-}) = 3.235$  (m)  $\delta_{\text{PAMAM}}(-\text{NHCOCH}_2\text{CH}_2\text{COOH}) = 3.420$  (t)  $\delta_{\text{PAMAM}}$  (protons next to tertiary amines) = 2.66 – 2.80 (m)

## 2.4 Conjugation of Ac<sub>3</sub>ManNAz to PEG-PAMAM [G3.0]

25 mL round bottom flask was charged with succinamic terminated mPE-G3.0 (55.0 mg, 0.0125 mmol), DCC (46.46 mg, 0.225 mmol), DMAP (27.50 mg, 0.225 mmol) and dissolved in anhydrous chloroform(6.00 mL) at ice bath under nitrogen atmosphere. Add Ac<sub>3</sub>ManNAz (58.29 mg, 0.150 mmol) to round bottom flask. Remove DCU by using syringe filter and evaporate chloroform. The excess reactants were dialyzed in DMSO for 72 hours using a cellulose membrane (MWCO 2,000 : Spectrum Laboratories, TX, USA). After dialysis, the Ac<sub>3</sub>ManNAz conjugated PEG-PAMAM [G3.0] was obtained by lyophilization.

## **2.5 Preparation of self assembly**

In 10 mL round bottom flask, pMP(10.0 mg) was dissolved in 3 mL chloroform. Chloroform was evaporated by rotary evaporator at 55 °C. Add 1 mL of H<sub>2</sub>O and stirred at 60 °C for 30 min. The solution was passed through 0.22 µm syringe filter. Before DLS analysis, the sample was diluted with 2 mL of H<sub>2</sub>O. Size of self assembly was characterized by DLS.

## **2.6 *In vitro* release of Ac<sub>3</sub>ManNAz**

To observe of release of Ac<sub>3</sub>ManNAz from pMP *in vitro*, Ac<sub>3</sub>ManNAz (10.0 mg) was dissolved in DPBS(1x) (2.0 ml) solution. The samples were sampled at 0, 3, 12, 24 h and dried by lyophilization. Obtained samples were dissolved in THF and salt was removed by PVDF syringe filters (0.22 µm). The samples were analyzed by GPC system.

## **2.7 Cell culture**

HT-29 (Human colon adenocarcinoma) cells were purchased from ATCC (Manassas, VA, USA). Those cell lines were maintained in RPMI1640 (Welgene, Daegu, Korea) containing 10% fetal bovine serum (FBS; Welgene, Daegu, Korea), 100 µg/ml streptomycin, and 100 U/ml penicillin (Welgene, Daegu, Korea) in a humidified 5% CO<sub>2</sub> atmosphere at 37°C.

## **2.8 Cell viability Assay**

HT-29 cells were seeded on 96-well plates ( $5 \times 10^3$  cells/well) and incubated for one day. To measure the cytotoxicity of pMPs, the cells were treated with pMPs with various concentration of Ac<sub>3</sub>ManNAz: 1.25, 2.5, 5, 10, 20  $\mu$ M. After incubation for two days, the cells were washed twice with DPBS (pH 7.4) and 20  $\mu$ L of MTT in serum-free RPMI1640 media (0.5 mg/mL) was added to each well. After further incubation for 2 h at 37 °C, the media was removed and cells were dissolved in 200  $\mu$ L of DMSO. Then, the absorbance of each well was measured at 572 nm using a microplate reader (VERSAmax™, Molecular Devices Corp., Sunnyvale, CA).

## **2.9 Cellular imaging to determine the generated azide groups**

U87 and HDF cells were seeded onto 35 mm glass-bottom dishes at a density of  $2.5 \times 10^5$  cells in 2 mL of media with various concentration of pMPs (0, 2.5, 5.0, 10.0, 20.0  $\mu$ M Ac<sub>3</sub>ManNAz). After incubation for two days, the cells were washed twice with DPBS (pH 7.4) and incubated for 1 hour with ADIBO-Cy5.5 (20  $\mu$ M, final concentration) (Future Chem, Seoul, Korea) in 37 °C incubator. They were rinsed with DPBS (pH 7.4) and fixed with a fixative containing 4 % paraformaldehyde for 10 min at room temperature. Then, the cells were washed with DPBS (pH 7.4) again and stained with DAPI (Invitrogen, Carlsbad, CA, USA) to label nuclei. All

cellular images were obtained by a confocal laser microscope (Leica TCS SP8, Leica Microsystems GmbH, Germany) with 405 diode (405 nm) and He-Ne (633nm) lasers.

## **2.10 Western blot analysis of cells**

HT-29 cells were seeded onto 100 x 20 mm cell culture plates at a density of  $2 \times 10^6$  cells per plate in 12 mL of media with Ac<sub>4</sub>ManNAz (20  $\mu$ M) or pMPs (20  $\mu$ M Ac<sub>3</sub>ManNAz). After 2 days of incubation, the cells were washed twice with DPBS (pH 7.4) and harvested from the plates using a cell scraper. The cells were pelleted by centrifugation at 1500 rpm for 5 min, and the cell pellets were re-suspended in 500  $\mu$ l of lysis buffer (1 % SDS, 100 mM Tris·HCl, pH 7.4) containing protease inhibitor cocktail (Complete, EDTA-free, Roche, NSW, Australia). They were lysed with a probe-type sonifier at 4 °C. Sonicated lysates were incubated at 4 °C for 30 min to further solubilized proteins, and insoluble debris was removed by centrifugation for 10 min at 3,000 x g. Final soluble protein concentrations were determined by bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL, USA) to be 5 mg/ml. Then, 20  $\mu$ l of the lysate was incubated with 2  $\mu$ l of phosphine-PEG<sub>3</sub>-biotin (5 mM in DPBS) (Pierce, Rockford, IL, USA) for 6 hours at 37 °C. SDS-PAGE loading buffer was added to each sample and the samples were heated at 95 °C, before loading onto 10% SPS-PAGE gel. Proteins were transferred to Hybond P membrane (Amercham, St.

Albans, UK), and the membrane was blocked with 5 % bovine serum albumin (BSA) in TBST (50 mM Tris·HCl, 150 mM NaCl, 0.1 % Tween20, pH 7.4) for 2 hours. Then, the membrane was incubated with streptavidin-HRP (diluted 1:2000 in TBST) (Pierce, Rockford, IL, USA) overnight at 4 °C. The membrane was rinsed three times with TBST and developed by ECL Western Blotting Substrate (Pierce, Rockford, IL, USA).

### 3. RESULTS AND DISCUSSION


#### 3.1 Synthesis and characterization of succinamic acid terminated PEG-PAMAM [G3.0]

PEG-PAMAM linear dendritic block copolymers (LDBC) were used as a backbone structure of the polymerized metabolic precursors (pMPs). Despite the advantages of dendrimers in high surface functionality and delivery efficiency, there was a limit to its use due to the synthetic barriers such as difficult purification process. By using mPEG-NH<sub>2</sub> as a core initiator, PEG-PAMAM LDBCs were easily synthesized. Purification is accomplished by simple precipitation.

PEG-PAMAM LDBC were successfully synthesized up to 3<sup>rd</sup> generation via iterative Michael addition and amidation reaction. Synthetic schemes of PEG-PAMAM LDBC are illustrated in scheme 1. In Michael addition reaction, we confirm that all of primary and secondary amines were consumed using the ninhydrin and chloranil test. The 100 % conversion in the amidation reaction was determined by disappearance of hydrogen peak of methyl esters in <sup>1</sup>H-NMR spectra. Terminal amine groups of PEG-PAMAM [G3] were converted to carboxylic acid by reacting succinic anhydride and characterized by <sup>1</sup>H-NMR and ninhydrin test.

<sup>1</sup>H-NMR spectra of each compound are shown in Figure 2.





**Scheme 1.** Synthetic Scheme of Succinamic Terminated PEG-PAMAM [G3] Linear Dendritic Block Copolymers




Figure 2.  $^1\text{H}$  NMR spectra of (a) mPEG-G0.5 and (b) mPEG-G1.0 in  $\text{CDCl}_3$




Figure 2.  $^1\text{H}$  NMR spectra of (c) mPEG-G1.5 and (d) mPEG-G2.0 in  $\text{CDCl}_3$




Figure 2.  $^1\text{H}$  NMR spectra of (e) mPEG-G2.5 in  $\text{CDCl}_3$  and (f) mPEG-G3.0 in  $\text{D}_2\text{O}$





Figure 2.  $^1\text{H}$  NMR spectra of (g) mPEG-G3.0-COOH in  $\text{D}_2\text{O}$

### 3.2 Synthesis and characterization of pMPs

For metabolic labeling of tumor cells, we use Ac<sub>3</sub>ManNAz as a metabolic building block. Because Ac<sub>3</sub>ManNAz can easily produce unnatural sialic acid, overexpressed in various kind of tumors.

PEG-PAMAM [G3] LDBC and Ac<sub>3</sub>ManNAz was conjugated by *Steglich* esterification (Scheme 2). The reaction was carried out for 5 days. Crude products were dialyzed in DMSO to inhibit hydrolysis of ester bonds for 3 days. After the reaction, pMPs were analyzed by <sup>1</sup>H NMR (Figure 3) and the <sup>1</sup>H NMR spectrum promised that 5.7 Ac<sub>3</sub>ManNAz was conjugated. Also, shift of the peak molecular weight without noticeable shoulders in the trace of GPC indicated successful conjugation of mPEG-G3.0 and Ac<sub>3</sub>ManNAz (Figure 4).



**Scheme 2.** Synthetic Prodcedure of pMPs.




Figure 3.  $^1\text{H}$  NMR spectra of (a)  $\text{Ac}_3\text{ManNAz}$  and (b) pMPs in  $\text{D}_2\text{O}$






Figure 4. GPC spectra of pMPs and mPEG-G3.0.

### **3.3 Formation of Self-assembly**

By conjugating Ac<sub>3</sub>ManNaz to PEG-PAMAM, the carboxylic acid at the terminal of the dendron disappears and the pMPs become amphiphilic block copolymers that can form self assemblies in aqueous condition.

The size of self-assembly was analyzed to be about 150 nm by DLS, which is a suitable size to exhibit the EPR effect (Figure 5). Its size was measured relatively larger than size of linear block copolymers. This is consistent with previous research about self assemble behavior of LDBC<sup>17-18</sup>.




Figure 5. Size distribution of self-aggregates

### **3.4 *In vitro* release of Ac<sub>3</sub>ManNAz**

Only free form of Ac<sub>3</sub>ManNAz can act as a building block in cell metabolism, therefore establishing the release of free Ac<sub>3</sub>ManNAz is important. Since tertiary amines in PAMAM play role as a catalyst, degradation rate of ester bonds in pMPs was relatively faster than other ester bonds<sup>19</sup>.

Hydrolysis of the ester bonds leads to a decrease in molecular weight and secretion of Ac<sub>3</sub>ManNAz. These phenomenons were obserbed by GPC (Figure 6). Relase of Ac<sub>3</sub>ManNAz was started from 3 hours, and amount of it was gradually increased to 24 hours.




Figure 6. GPC spectra of pMPs on time-dependent hydrolysis

### 3.5 *In vitro* studies of pMPs

Purpose of *in vitro* studies is proving the expression of chemical receptors on tumor cell surface. Despite treatment with 20  $\mu$ M of pMPs for 48 hours, no cytotoxicity was observed (Figure 7). Generation of azide groups was visualized by ADIBO-Cy5.5. Since ADIBO has high reactivity to azide groups in physiological condition without any catalysts<sup>20</sup>, ADIBO is chosen as complementary bioorthogonal functional groups. Fluorescence intensity was depends on concentration of pMPs, and we decided that 20  $\mu$ M was the optimal concentration for cellular imaging (Figure 8a). Western blot analysis using phosphine-PEG-biotin and streptavin-HRP demonstrated the generation of azide containing glycoprotein on the tumor cell surfaces after treatment of pMPs (Figure 8b). In addition, when the expression of the azide groups was visualized with time, it did not expressed until 6 hours and reached the peak at 48 hour after pMPs treatment. Time-dependent azide group expression was also proved by western blot analysis (Figure 9 a,b). The tendency of expression of azide groups with time is consitent with *in vitro* release experimental data.






Figure 7. Viability of HT-29 cells treated with pMPs for 48 hours



**Figure 8.** Azide group generation on cell surface in various concentration of pMPs (a) Visualization of azide groups on the surface of HT-29 tumor cells (b) Coomassie staining and wetern blot analysis of HT-29 tumor cells





**Figure 9.** Time dependent azide group generation on cell surface after pMPs treatment (a) Visualization of azide groups on the HT-29 tumor cell surface (b) Coomassie staining and wetern blot analysis of HT-29 tumor cell

## 4. CONCLUSION

In this study, we developed polymerized metabolic precursors (pMPs) using PEG-PAMAM LDBC and Ac<sub>3</sub>ManNAz. PEG-PAMAM [G3] was used as a backbone structure of the pMPs. By using mPEG-NH<sub>2</sub> as a starting material, all the purification steps required for the PEG-PAMAM synthesis were carried out by the simple precipitation method. PEG-PAMAM LDBCs were conjugated to Ac<sub>3</sub>ManNAz via *Steglich* esterification to produce hydrolyzable pMPs. Since the amphiphilic nature of pMPs, it can form self aggregates in aqueous condition. The size of self assembly was about 150 nm, applicable size to exhibit the EPR effect.

*In vitro* studies showed that pMPs did not show cytotoxicity up to 20  $\mu$ M and generation of azide groups on the tumor cell surface was confirmed by western blot analysis. Furthermore the ‘receptore-like’ azide groups could be labeled with ADIBO-Cy5.5 via copper free click chemistry.

The results from *in vitro* studies supported succesful preparation of pMPs and this strategy based on metabolic glycoengineering and copper free click chemistry will provide platform technology to overcome tumor heterogeneity.

## 5. REFERENCES

1. Kayser, H.; Zeitler, R.; Kannicht, C.; Grunow, D.; Nuck, R.; Reutter, W., BIOSYNTHESIS OF A NONPHYSIOLOGICAL SIALIC-ACID IN DIFFERENT RAT ORGANS, USING N-PROPANOYL-D-HEXOSAMINES AS PRECURSORS. *J. Biol. Chem.* **1992**, *267* (24), 16934-16938.
2. Keppler, O. T.; Stehling, P.; Herrmann, M.; Kayser, H.; Grunow, D.; Reutter, W.; Pawlita, M., BIOSYNTHETIC MODULATION OF SIALIC ACID-DEPENDENT VIRUS-RECEPTOR INTERACTIONS OF 2 PRIMATE POLYOMA VIRUSES. *J. Biol. Chem.* **1995**, *270* (3), 1308-1314.
3. Saxon, E.; Bertozzi, C. R., Cell surface engineering by a modified Staudinger reaction. *Science* **2000**, *287* (5460), 2007-2010.
4. Saxon, E.; Luchansky, S. J.; Hang, H. C.; Yu, C.; Lee, S. C.; Bertozzi, C. R., Investigating cellular metabolism of synthetic azidosugars with the Staudinger ligation. *J. Am. Chem. Soc.* **2002**, *124* (50), 14893-14902.
5. Cohen, A. S.; Dubikovskaya, E. A.; Rush, J. S.; Bertozzi, C. R., Real-Time Bioluminescence Imaging of Glycans on Live Cells. *J. Am. Chem. Soc.* **2010**, *132* (25), 8563-+.

6. Baskin, J. M.; Dehnert, K. W.; Laughlin, S. T.; Amacher, S. L.; Bertozzi, C. R., Visualizing enveloping layer glycans during zebrafish early embryogenesis. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, *107* (23), 10360-10365.
7. Laughlin, S. T.; Agard, N. J.; Baskin, J. M.; Carrico, I. S.; Chang, P. V.; Ganguli, A. S.; Hangauer, M. J.; Lo, A.; Prescher, J. A.; Bertozzi, C. R., Metabolic labeling of glycans with azido sugars for visualization and glycoproteomics. In *Glycobiology*, Fukuda, M., Ed. Elsevier Academic Press Inc: San Diego, 2006; Vol. 415, pp 230-250.
8. Bagalkot, V.; Farokhzad, O. C.; Langer, R.; Jon, S., An Aptamer–Doxorubicin Physical Conjugate as a Novel Targeted Drug Delivery Platform. *Angewandte Chemie International Edition* **2006**, *45* (48), 8149-8152.
9. Park, E. K.; Kim, S. Y.; Lee, S. B.; Lee, Y. M., Folate-conjugated methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric micelles for tumor-targeted drug delivery (vol 109, pg 158, 2005). *J. Control. Release* **2006**, *112* (1), 145-146.
10. Dharap, S. S.; Wang, Y.; Chandna, P.; Khandare, J. J.; Qiu, B.; Gunaseelan, S.; Sinko, P. J.; Stein, S.; Farmanfarmaian, A.; Minko, T., Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. *Proc. Natl. Acad. Sci. U. S. A.* **2005**, *102* (36), 12962-12967.
11. Gerlinger, M.; Rowan, A. J.; Horswell, S.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.;

- Tarpey , P.; Varela , I.; Phillimore , B.; Begum , S.; McDonald , N. Q.;  
Butler , A.; Jones , D.; Raine , K.; Latimer , C.; Santos , C. R.; Nohadani ,  
M.; Eklund , A. C.; Spencer-Dene , B.; Clark , G.; Pickering , L.; Stamp , G.;  
Gore , M.; Szallasi , Z.; Downward , J.; Futreal , P. A.; Swanton , C.,  
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion  
Sequencing. *New England Journal of Medicine* **2012**, *366* (10), 883-892.
12. Meric-Bernstam, F.; Mills, G. B., Overcoming implementation  
challenges of personalized cancer therapy. *Nat. Rev. Clin. Oncol.* **2012**, *9* (9),  
542-548.
13. Burrell, R. A.; McGranahan, N.; Bartek, J.; Swanton, C., The causes  
and consequences of genetic heterogeneity in cancer evolution. *Nature* **2013**,  
*501* (7467), 338-345.
14. Park, J. W.; Hong, K. L.; Kirpotin, D. B.; Colbern, G.; Shalaby, R.;  
Baselga, J.; Shao, Y.; Nielsen, U. B.; Marks, J. D.; Moore, D.;  
Papahadjopoulos, D.; Benz, C. C., Anti-HER2 immunoliposomes: Enhanced  
efficacy attributable to targeted delivery. *Clin. Cancer Res.* **2002**, *8* (4),  
1172-1181.
15. Fuster, M. M.; Esko, J. D., The sweet and sour of cancer: Glycans  
as novel therapeutic targets. *Nat. Rev. Cancer* **2005**, *5* (7), 526-542.
16. Nakanishi, T.; Fukushima, S.; Okamoto, K.; Suzuki, M.; Matsumura,  
Y.; Yokoyama, M.; Okano, T.; Sakurai, Y.; Kataoka, K., Development of the

- polymer micelle carrier system for doxorubicin. *J. Control. Release* **2001**, *74* (1-3), 295-302.
17. del Barrio, J.; Oriol, L.; Sanchez, C.; Serrano, J. L.; Di Cicco, A.; Keller, P.; Li, M. H., Self-Assembly of Linear-Dendritic Diblock Copolymers: From Nanofibers to Polymersomes. *J. Am. Chem. Soc.* **2010**, *132* (11), 3762-3769.
18. Lin, Y. L.; Chang, H. Y.; Sheng, Y. J.; Tsao, H. K., Photoresponsive Polymersomes Formed by Amphiphilic Linear-Dendritic Block Copolymers: Generation-Dependent Aggregation Behavior. *Macromolecules* **2012**, *45* (17), 7143-7156.
19. Bruice, P. Y.; Bruice, T. C., INTRAMOLECULAR GENERAL BASE-CATALYZED HYDROLYSIS AND TERTIARY AMINE NUCLEOPHILIC-ATTACK VS GENERAL BASE-CATALYZED HYDROLYSIS OF SUBSTITUTED PHENYL QUINOLINE-8-CARBOXYLATE AND QUINOLINE-6-CARBOXYLATES. *J. Am. Chem. Soc.* **1974**, *96* (17), 5523-5532.
20. Sletten, E. M.; Bertozzi, C. R., Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality. *Angew. Chem.-Int. Edit.* **2009**, *48* (38), 6974-6998.

## 요약문

화학요법은 항암제를 이용하여 암을 치료하는 것이다. 항암제는 암세포에 작용한다면 약이지만, 정상세포에 작용한다면 독성을 야기한다. 따라서 종양에만 선택적으로 약물을 전달하는 약물 전달 체계가 화학요법에 있어 매우 중요하다. 약물 전달 체계에 대한 다양한 연구가 진행되면서 종양 세포만을 표적으로 할 수 있는 타게팅 모이티들이 많이 개발되었다. 하지만 종양세포의 이질성과 표적화 생체 분자의 양적한계 때문에 화학요법을 통한 암의 완치에 실패하였다.

이러한 한계점들을 극복하기 위하여, 본 연구에서는 고분자화 대사전구체를 이용하여 암 조직에 인공 표적 수용체를 도입하였다. PEG-PAMAM 과 Triacetylated-N-azido acetyl-D-mannosamine(Ac<sub>3</sub>ManNAz)의 화학적 결합을 통해 수용성 고분자화 대사 전구체를 합성하였으며, 이 물질은 수용액 상에서 150 nm 의 자가 조립체를 형성하였다. 세포 실험을 통하여 암의 표현 형질과 관계 없이 모든 종양 세포가 azide 기를 발현하는 것과 생리 조건에서 azide 기가 무동 클릭 화학을 통해 표적화 될 수 있음을 확인하였다. 본 연구에서 개발된 고분자화 대사

전구체를 생체 실험에 사용할 경우, 자가 조립체의 enhanced permeability and retention (EPR) 효과와 종양세포의 시알산 과다 발현을 통해 종양세포에만 특이적으로 azide 기를 도입할 수 있으며, 무동 클릭 화학을 통한 azide 기 표적화를 통해 약물 전달 효율을 증가시킬 수 있을 것으로 기대된다.

주요 어: 종양 이질성, 후성 표적화 전략, 고분자화 대사 전구체, 당 대사 공학, 무동 클릭 화학, 광학 이미징

학번: 2015-20797